Greenland Mines (GRML)

The company’s licensed assets include a generic drug portfolio and a biosimilar biologics platform. Generic medicines are typically developed to offer equivalent versions of established drugs after exclusivity periods expire, while biosimilars are highly similar versions of approved biologic therapies. In oncology and other complex disease areas, biosimilars can play an important role by broadening access to biologic treatments, although development requires substantial technical, regulatory, and manufacturing expertise.

Greenland Mines Ltd. also holds proprietary technologies involving melanocortin receptor-binding molecules. Melanocortin receptors are involved in a range of biological processes, including inflammation and metabolic signalling, making them a potential target class for therapeutic research. In addition, the company references a gene therapy platform designed to deliver Klotho, a protein associated in scientific literature with ageing biology and neuroprotective pathways, into the body for possible use in neurodegenerative disease.

As a listed development-stage healthcare company, its investment profile depends heavily on the maturity of its programmes, intellectual property, clinical validation, regulatory progress, and access to funding. The stock represents exposure to a speculative biotechnology pipeline rather than to a commercialised pharmaceutical franchise.